OBJECTIVE To prospectively assess whether low-molecular-weight heparin (LMWH)
provides a survival benefit in patients with advanced cancer. PATIENTS AND METHODS …

Background: Low‐molecular‐weight heparins (LMWH) have an antitumor effect in vitro and
in experimental animal models of malignancy. Retrospective data suggest that it might …

Background Tumors may exploit the coagulation system to enhance the survival and
dissemination of cancer cells. Some studies have suggested that heparin and low molecular …

BACKGROUND: Low-molecular-weight heparin (LMWH) has an anti-tumour effect in-vitro
and in animal models of malignancy; however, the evidence from clinical trials is …

Work with low-molecular-weight heparins (LMWHs) continues to provide suggestions for
survival advantages among patients with cancer diagnoses. Momentum is building in …

Purpose Studies in cancer patients with venous thromboembolism suggested that low
molecular weight heparin may prolong survival. In a double-blind study, we evaluated the …

Heparin is a familiar anticoagulant drug with properties that may impede tumor growth; it
modifies properties of cells that contribute to malignant dissemination such as angiogenesis …

Introduction The relationship between cancer and thrombosis is complex, as the hemostatic
system is inextricably linked to the mechanisms of cancer growth and metastasis. The …

The influence of unfractionated heparin (UFH) and other anticoagulants on the spread of
cancer has been reported since the early 1960s. 1 However, clinical studies investigating …

Objectives. Venous thromboembolism (VTE) occurs more frequently in cancer patients than
in non-cancer patients and outcomes are poor in patients with both cancer and thrombosis …